Companies

Natco Pharma Q4 net down 22.5% at ₹93 cr

Our Burea Hyderabad | Updated on June 17, 2020 Published on June 17, 2020

Natco Pharma Ltd’s consolidated net profit declined 22.5 per cent to ₹93 crore in the fourth quarter ended March 31, against ₹120 crore profit recorded in the corresponding quarter last year.

The total revenue of the Hyderabad-based company was marginally down at ₹477 crore (₹487 crore).

For the full year ended March 31, the drug maker posted 9 per cent decline in revenue at ₹2,022 crore against ₹2,225 crore in previous fiscal. The net profit for the period declined 29 per cent to ₹458 crore (₹642 crore).

“The overall decline in revenue and profits, from the prior year, was primarily due to continued decline in Hepatitis C product portfolio and to an extent in oncology segment due to pricing pressures,’’ the company said in a release.

The company also faced slowdown in business operations during the fourth quarter due to supply chain issues amidst Covid-19 concerns, which were subsequently resolved, it added.

The board of directors recommended a fourth interim dividend of ₹1.00 per equity share of ₹2 each, resulting in a total dividend payout of ₹6.75 per equity share for the year.

Published on June 17, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
Amara Raja Group takes to digital transformation with SAP solution across 6 group companies and 14 business verticals